It is difficult to conceive of practicing dermatology today without access to the clinical use of corticosteroids given for systemic effects, yet these potent antiphlogistic agents have been available for only 30 years. The centennial article by Sulzberger et al introduced these drugs to the clinical dermatologist and began a revolutionary new era of anti-inflammatory therapy for dermatologic disorders.1 Dermatoses which were previously poorly or completely unresponsive to the available treatment modalities responded, often in a dramatic fashion, to oral cortisone acetate therapy, with or without supplemental corticotrophin. The prescience of these authors was remarkable. In their comprehensive article, they recorded their experience in treating a large series of patients with a variety of dermatoses and tabulated concisely many of the crucial variables needed to assess the efficacy of these new "wonder" drugs, namely, initialand maintenance-dose requirements, response, duration of treatment, and course after stopping medication. In addition,